Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

PHASE4CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

August 31, 2019

Conditions
ITP
Interventions
DRUG

TPO

Trial Locations (21)

110001

The First Hospital of China Medical University, Shenyang

150010

Harbin Institute of Hematology and Oncology, Haerbin

150040

First Affiliated Hospital Heilongjiang University of Chinese Medicine, Shenyang

215000

The Second Affiliated Hospital of Soochow University, Suzhou

230022

The First Affiliated Hospital of Anhui Medical University, Hefei

300020

Chinese Academy of Medical Sciences Blood Disease Hospital, Tianjin

310006

Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine, Hangzhou

323000

Lishui City Center Hospital, Lishui

361004

Zhongshan Hospital Xiamen University, Xiamen

417118

Loudi Central Hospital, Loudi

430060

renmin Hospital of Wuhan University Hubei General Hospital, Wuhan

450000

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou

450007

Zhengzhou Central Hospital, Zhengzhou

453699

Xinxiang Central Hospital,, Xinxiang

471003

Henan University of Science and Technology First Affiliated Hospital, Luoyang

510260

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

510317

Guangdong Second People's Hospital, Guangzhou

511400

Guangzhou Panyu Central Hospital, Guangzhou

710499

Xi An Central Hospital, Xi’an

Unknown

Xinjiang Uygur Autonomous Region Chinese Medicine Hospital,, Ürümqi

The First Affiliated Hospital of Xinjiang Medical University, Xinjiang

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY

NCT04089267 - Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter